The Duke Human Vaccine Institute (DHVI) has established a place of national and international leadership in the fight against major infectious diseases. DHVI plays an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and is a pioneer in emerging infections and biodefense research. By focusing on the scientific “bottlenecks” for the development of HIV, TB, and other vaccines, DHVI investigators continue to make significant contributions to overcome global health challenges on behalf of society. More

Press Releases

Human Immunodeficiency Virus

Recent Publications

Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 Vaccinees.
Moody MA, Easterhoff D, Gurley TC, Whitesides JF, Marshall DJ, Foulger A, Lloyd KE, Parks R, Pollara J, Duffy R, Shen S, Kim JH, Michael NL, Robb ML, O'Connell RJ, Vasan S, Excler JL, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Francis D, Lee C, Kepler TB, Alam SM, Ferrari G, Montefiori DC, Liao HX, Tomaras GD, Haynes BF. AIDS Res Hum Retroviruses. 2014 Oct; 30(S1): A36. No abstract available.

Role of Intestinal Microbiota in Shaping the B Cell Repertoire in HIV Infection and Env Vaccination.
Liao LH, Trama AM, Williams WB, Moody MA, Vandergrift N, Tomaras GD, Marshall DJ, Gurley T, Whitesides J, Eudailey J, Foulger A, Parks R, Stolarchuk C, Lloyd KE, Soderberg K, Mascola JR, Koup R, Corey L, Nabel GB, Gilber P, Morgan C, Maenza J, Keefer M, Hammer S, Churchyard G, Montefior DC, Graham BS, Baden LR, Kepler TB, Haynes BF. AIDS Res Hum Retroviruses. 2014 Oct; 30(S1): A19. No abstract available.

Polyreactivity and Autoreactivity among HIV-1 Antibodies.
Liu M, Yang G, Wiehe K, Nicely NI, Vandergrift NA, Rountree W, Bonsignori M, Alam SM, Gao J,Haynes BF, Kelsoe G. J Virol. 2014 Oct 29. pii: JVI.02378-14. [Epub ahead of print]

Video Presentations

Broadly neutralizing HIV-1 antibody identified in a lupus patient
March 11, 2014
Dr. Barton Haynes, DHVI and Duke CHAVI-ID Director, discusses recent findings from a study led by DHVI investigators in which a broadly neutralizing antibody was identified in a lupus patient who was chronically infected with HIV.